HRT and GLP-1: Safety and professional guidance While the potential benefits of combining these two therapies are significant, they can both have side effects and safety issues that need to be considered
For people managing diabetesor anyone already taking insulin or oral glucose-lowering medicationthis overlap can be particularly risky
Also, theyre very informative
Sin embargo, incluso en entornos populares, resulta esencial establecer un presupuesto claro, usar lmites de depsito y sesiones temporizadas para mantener el control
Once-weekly formulations like semaglutide reach steady-state concentrations after approximately 45 weeks, while dulaglutide typically reaches steady state in 24 weeks
Matsui K, Hasegawa J, Tachibana M